Anemia is common in patients with chronic kidney disease and is associated with a high
burden of morbidity and adverse clinical outcomes. In 2012, Kidney Disease: Improving …

Chronic kidney disease (CKD) affects approximately 10% of the worldwide population;
anaemia is a frequent complication. Inadequate erythropoietin production and absolute or …

For the past 3 decades, erythropoiesis-stimulating agents (ESA) in conjunction with iron
supplementation has been the mainstay of treatment for anemia in chronic kidney disease …

Renal anemia in chronic kidney disease (CKD) is associated with poor outcomes. Hypoxia-
inducible factor (HIF) stabilizer, which induces endogenous erythropoietin synthesis and …

The production of erythropoietin (EPO), the main regulator of erythroid differentiation, is
regulated by hypoxia-inducible factor (HIF). HIF2α seems to be the principal regulator of …

Background Hypoxia-inducible factor prolyl hydroxylase inhibitors (HIF-PHIs) are new
therapeutic agents for anaemia in chronic kidney disease (CKD). We evaluated by meta …

Anemia is a common complication of chronic kidney disease; it is mainly treated with
erythropoiesis-stimulating agents (ESAs) and iron. Experimental studies extensively …

Aim: We performed a systematic review and network meta-analysis evaluating the safety
and efficacy of hypoxia-inducible factor prolyl hydroxylase inhibitors (HIF-PHIs) among …

Background: Five types of HIF-PHIs have been authorized for anemia treatment in CKD
patients in China and Japan. These are enarodustat, roxadustat, daprodustat, vadadustat …

Hypoxia-inducible factor prolyl hydroxylase enzyme inhibitor... : Current Opinion in Nephrology
and Hypertension Hypoxia-inducible factor prolyl hydroxylase enzyme inhibitors: ready for …